INSM vs. SRPT
INSM (Insmed Incorporated) and SRPT (Sarepta Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, INSM returned 26.23%/yr vs -0.48%/yr for SRPT. At a 0.26 correlation, their price movements are largely independent.
Performance
INSM vs. SRPT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, INSM achieves a -43.34% return, which is significantly lower than SRPT's -17.98% return. Over the past 10 years, INSM has outperformed SRPT with an annualized return of 26.23%, while SRPT has yielded a comparatively lower -0.48% annualized return.
INSM
- 1D
- 2.93%
- 1M
- -7.19%
- YTD
- -43.34%
- 6M
- -43.90%
- 1Y
- -3.97%
- 3Y*
- 70.31%
- 5Y*
- 28.78%
- 10Y*
- 26.23%
SRPT
- 1D
- 0.68%
- 1M
- 5.06%
- YTD
- -17.98%
- 6M
- -16.86%
- 1Y
- -12.10%
- 3Y*
- -46.32%
- 5Y*
- -25.78%
- 10Y*
- -0.48%
INSM vs. SRPT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
INSM Insmed Incorporated | -43.34% | 152.09% | 122.78% | 55.11% | -26.65% | -18.17% | 39.41% | 82.01% | -57.92% | 135.68% |
SRPT Sarepta Therapeutics, Inc. | -17.98% | -82.30% | 26.09% | -25.58% | 43.90% | -47.18% | 32.12% | 18.24% | 96.14% | 102.84% |
Correlation
The correlation between INSM and SRPT is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.40 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.41 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2000 | 0.26 |
The correlation between INSM and SRPT shifts across timeframes, from 0.26 (all time) to 0.41 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
INSM:
$21.25B
SRPT:
$2.15B
INSM:
-$5.71
SRPT:
$0.60
INSM:
24.96
SRPT:
0.88
INSM:
30.14
SRPT:
1.43
INSM:
$819.56M
SRPT:
$2.18B
INSM:
$668.55M
SRPT:
$751.34M
INSM:
-$1.14B
SRPT:
$107.91M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
INSM vs. SRPT — Risk / Return Rank
INSM
SRPT
INSM vs. SRPT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Insmed Incorporated (INSM) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| INSM | SRPT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.05 | ||
| Sortino ratioReturn per unit of downside risk | -0.25 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.07 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | -0.07 | -0.27 | +0.20 |
| Martin ratioReturn relative to average drawdown | -0.16 | -0.59 | +0.43 |
Loading charts...
Drawdowns
INSM vs. SRPT - Drawdown Comparison
The maximum INSM drawdown since its inception was -98.65%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for INSM and SRPT.
Loading charts...
Drawdown Indicators
| INSM | SRPT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.65% | -98.17% | -0.48% |
Max Drawdown (1Y)Largest decline over 1 year | -56.54% | -45.70% | -10.84% |
Max Drawdown (3Y)Largest decline over 3 years | -56.54% | -92.72% | +36.18% |
Max Drawdown (5Y)Largest decline over 5 years | -56.54% | -92.72% | +36.18% |
Max Drawdown (10Y)Largest decline over 10 years | -64.84% | -93.33% | +28.49% |
Current DrawdownCurrent decline from peak | -53.36% | -90.13% | +36.77% |
Average DrawdownAverage peak-to-trough decline | -86.05% | -68.19% | -17.86% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.87% | 20.66% | +4.21% |
Volatility
INSM vs. SRPT - Volatility Comparison
Insmed Incorporated (INSM) has a higher volatility of 17.30% compared to Sarepta Therapeutics, Inc. (SRPT) at 15.85%. This indicates that INSM's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| INSM | SRPT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.30% | 15.85% | +1.45% |
Volatility (6M)Calculated over the trailing 6-month period | 46.26% | 52.73% | -6.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.19% | 94.28% | -42.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.88% | 69.84% | +3.04% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.49% | 70.37% | +8.12% |
Dividends
INSM vs. SRPT - Dividend Comparison
Neither INSM nor SRPT has paid dividends to shareholders.
Financials
INSM vs. SRPT - Financials Comparison
This section allows you to compare key financial metrics between Insmed Incorporated and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
INSM vs. SRPT - Profitability Comparison
INSM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported a gross profit of 258.54M and revenue of 305.96M. Therefore, the gross margin over that period was 84.5%.
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.
INSM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported an operating income of -198.20M and revenue of 305.96M, resulting in an operating margin of -64.8%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.
INSM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Insmed Incorporated reported a net income of -163.56M and revenue of 305.96M, resulting in a net margin of -53.5%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.
Frequently Asked Questions
INSM and SRPT have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
INSM has higher volatility (17.30%) compared to SRPT (15.85%). In terms of maximum drawdown, INSM dropped -98.65% vs SRPT's -98.17%.
INSM currently has the higher Sharpe Ratio (-0.08 vs -0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for INSM and SRPT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer